Sunday, October, 25, 2009
Tarceva
October 02, 2008
Adding Celebrex to the current lung cancer treatment Tarceva
increased response rates in patients by 33 percent in a new study
at the University of California. Researchers suggest that the
addition of Celebrex to Tarceva may help patients overcome their
resistance to Tarceva and thus help inhibit their tumors' growth.
Read more »
Expert & Community Posts
By Kevin Knopf, MD
,
Health Expert
Personalized medicine actually has two meanings. The first, and probably the one most familiar to...
Read more »
Health Guide
...tumors will respond to epidermal growth factor receptor (EGFR) kinase inhibitors such as erlotinib (
Tarceva) and gefitinib (Iressa), suggests a New England Journal of Medicine study.Radiotherapy...
Read more »
...talking to your doctor.Results from an ongoing study show that adding bevacizumab (Avastin) to erlotinib (
Tarceva) or to chemotherapy increases disease-free survival time. The study looked at...
Read more »
...disease-free survival time in patients with advanced NSCLC is longer when adding bevacizumab to erlotinib (
Tarceva) or to chemotherapy.Antisense OligonucleotideAntisense oligonucleotides are drugs...
Read more »
...you are currently taking gefitinib, do not stop taking it without talking to your doctor.Erlotinib (
Tarceva) is in the same medication class as gefitinib, but it shows very promising results in...
Read more »
...patients may respond to epidermal growth factor receptor (EGFR) kinase inhibitors, such as erlotinib (
Tarceva) and gefitinib (Iressa).A genetic profile can also help give doctors a better idea of...
Read more »
Related News
October 02, 2008
According to a new study, the cancer medication Tarceva may improve the chance of survival in patients with advanced pancreatic cancer. The results,...
Read summary »
July 11, 2008
By Kirsten Houmann, Ivanhoe Health Correspondent ORLANDO, Fla. (Ivanhoe Newswire) -- Better treatment may be on the horizon for lung cancer...
Read summary »